SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

Yumei Ye, Mandeep Bajaj, Hsiu Chiung Yang, Jose R. Perez-Polo, Yochai Birnbaum

Research output: Contribution to journalArticlepeer-review

138 Scopus citations

Fingerprint

Dive into the research topics of 'SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences